A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
11/2002
11/21/2002	WO2002092616A1 Antisense permeation enhancers
11/21/2002	WO2002092600A1 Retinol derivatives potentiation of active substances by micellar preparation
11/21/2002	WO2002092573A2 Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
11/21/2002	WO2002092339A1 Biodegradable and/or bioabsorbable fibrous articles and methods for using the articles for medical applications
11/21/2002	WO2002092217A1 Vegetable protein-based microcapsules
11/21/2002	WO2002092147A2 Optimization of the molecular properties and formulation of proteins delivered by inhalation
11/21/2002	WO2002092142A2 Polymeric corneal bandages/lenses for delivery of a pharmaceutical
11/21/2002	WO2002092130A1 Agent for improving tissue penetration
11/21/2002	WO2002092106A1 Taste masking pharmaceutical composition
11/21/2002	WO2002092099A1 Prostanoic acid derivatives as agents for lowering intraocular pressure
11/21/2002	WO2002092098A1 Method for treating ocular hypertension and glaucoma
11/21/2002	WO2002092097A1 Composition comprising phosphodiesterase inhibitors for inducing cervical ripening
11/21/2002	WO2002092085A1 Pharmaceutical compositions comprising chelidonine or derivatives thereof
11/21/2002	WO2002092078A1 Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
11/21/2002	WO2002092069A1 Permeation enhancers
11/21/2002	WO2002092067A1 Compositions for transmucosal administration containing coenzyme q as the active ingredient
11/21/2002	WO2002092064A2 Therapeutic method for inducing tolerance
11/21/2002	WO2002092061A1 Biorodible poly(orthoesters) from dioxolane-based diketene acetals
11/21/2002	WO2002092060A1 Abuse-resistant controlled-release opioid dosage form
11/21/2002	WO2002092059A1 Abuse-resistant opioid dosage form
11/21/2002	WO2002092058A1 Rapidly disintegratable solid preparation
11/21/2002	WO2002092056A1 Compaction process for manufacture of sodium phenytoin dosage form
11/21/2002	WO2002092054A2 Immune modulation device for use in animals
11/21/2002	WO2002092049A2 System for delivering cosmetics and pharmaceuticals
11/21/2002	WO2002092031A1 Topical compositions containing nonimmunosuppressive cyclosporin_derivatives for treating hair loss
11/21/2002	WO2002092028A2 Oral care compositions
11/21/2002	WO2002092013A2 Methods for treating liver disease and liver damage with growth hormone and foxm1b
11/21/2002	WO2002091995A2 Method to induce neovascular formation and tissue regeneration
11/21/2002	WO2002091966A1 Kavalactone compositions and methods of use
11/21/2002	WO2002091852A1 Oral delivery system and method for making same
11/21/2002	WO2002091833A1 Prebiotic and probiotic compositions and methods for their use in gut-based therapies
11/21/2002	WO2002078716A3 Methylated promoters for intraductal treatment of breast cancer
11/21/2002	WO2002074310A3 Stabilized formulation of selective ligands of retinoic acid gamma-receptors
11/21/2002	WO2002072034A3 Chronotherapeutic dosage forms
11/21/2002	WO2002066013A3 Liposome-mediated dna administration
11/21/2002	WO2002064148A3 Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
11/21/2002	WO2002064108A3 Delivery of biologically active agents
11/21/2002	WO2002062318A3 Oral itraconazole formulations and methods of making the same
11/21/2002	WO2002062317A3 Bimodal dry powder formulation for inhalation
11/21/2002	WO2002058674A3 Process for preparing particles
11/21/2002	WO2002047492A3 A moisture and oxygen stable composition and a process for obtaining said composition
11/21/2002	WO2002043788A3 Method and apparatus for delivery of therapeutic from a delivery matrix
11/21/2002	WO2002043785A3 Intraocular implants for preventing transplant rejection in the eye
11/21/2002	WO2002043765A3 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
11/21/2002	WO2002038136A3 Skin friendly active ingredient plaster for transdermal administration of etheric oils
11/21/2002	WO2002015877A8 Methods and compositions for targeted delivery
11/21/2002	WO2002005799A3 Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
11/21/2002	WO2001034646A9 Recombinant gelatins
11/21/2002	WO2001028511A9 Selective removal of contaminants from a surface using magnets
11/21/2002	US20020173851 Intervertebral disc treatment devices and methods
11/21/2002	US20020173830 Method and apparatus for communicating between an ambulatory medical device and a control device via telemetry using randomized data
11/21/2002	US20020173774 Low profile inlet valve for a piston pump therapeutic substance delivery device
11/21/2002	US20020173773 Permanent magnet solenoid pump for an implantable therapeutic substance delivery device
11/21/2002	US20020173772 Implantable therapeutic substance delivery device having a piston pump with an anti-cavitation valve
11/21/2002	US20020173745 Microfabricated devices for the delivery of molecules into a carrier fluid
11/21/2002	US20020173736 Plaster containing 4-biphenylacetic acid
11/21/2002	US20020173703 Ambulatory medical apparatus and method using a robust communication protocol
11/21/2002	US20020173702 Ambulatory medical apparatus and method using a robust communication protocol
11/21/2002	US20020173669 Steroid hormone products and methods for preparing them
11/21/2002	US20020173586 Thermogelling biodegradable aqueous polymer solution
11/21/2002	US20020173552 Erodible polymers for injection
11/21/2002	US20020173547 Pharmaceuticals compositions
11/21/2002	US20020173530 Single morphic forms of metalloproteinase inhibitors
11/21/2002	US20020173522 Pharmaceutical compositions comprising norastemizole
11/21/2002	US20020173516 Pharmaceutical compositions and methods for treating immune-response associated diseases of the surface and the anterior segment of the eye
11/21/2002	US20020173510 Nutrient mixture; fatty acid, calcium compound and vitamins
11/21/2002	US20020173498 Topical administering; skin disorders
11/21/2002	US20020173497 Stability; oral administering; anticancer agents
11/21/2002	US20020173496 Formulation containing novel anti-inflammatory androstane derivative
11/21/2002	US20020173485 Mixture of hyaluronic acid and polyvinylpyrrolidone
11/21/2002	US20020173484 Ingestion of hyaluronic acid for improved joint function and health
11/21/2002	US20020173472 Pharmaceutical formulations of resveratrol
11/21/2002	US20020173470 Jasmonate pharmaceutical composition for treatment of cancer
11/21/2002	US20020173467 Peptide in biopolymer; oil in water emulsion
11/21/2002	US20020173460 Complexing with fibronectins; analyzing, calibration; antiinflammatory agents, respiratory system disorders
11/21/2002	US20020173213 Variations blends of fibers; sustained release; drug delivery
11/21/2002	US20020173025 Human DNase I hyperactive variants
11/21/2002	US20020172826 Nanoscale catalyst compositions from complex and non-stoichiometric compositions
11/21/2002	US20020172727 Multiparticulate formulations of lithium salts for oral administration suitable for once-a-day administration
11/21/2002	US20020172724 Administering a beverage composition suitable for human consumption comprising effective amounts of the following solubilized components: calcium compound, acid, inulin to reduce the risk of bone density loss
11/21/2002	US20020172721 Vitamin formulation for cardiovascular health
11/21/2002	US20020172717 Instilling microparticle or nanoparticle comprising biocompatible polymer and therapeutic agent into a patient's bladder such that portion of instilled microparticle or nanoparticles are localized to lymph nodes; releasing
11/21/2002	US20020172716 Polymeric microspheres
11/21/2002	US20020172715 As carrier for use in microgravity tissue culture; for filling bone defect
11/21/2002	US20020172714 Pharmaceutical preparations and methods for their regional administration
11/21/2002	US20020172712 Antiemetic, anti-motion sustained release drug delivery system
11/21/2002	US20020172711 Fusogenic liposome formulation for delivering a liposome-entrapped compound into the cytoplasm of a target cell
11/21/2002	US20020172710 Utilizing liposomes as non-parenteral vehicles for delivery of nutrients into the blood of patients who have diseased or traumatized small bowels, and those who have undergone massive resections of small bowel with removal of ileum
11/21/2002	US20020172694 For therapy of abnormal cardiac activity; quick release and slow or delayed release pharmaceuticals
11/21/2002	US20020172677 Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
11/21/2002	US20020172672 Serine protease and topical retinoid compositions useful for treatment of acne vulgaris and production of anti-aging effects
11/21/2002	US20020172661 For diagnosis, prevention, or treatment of diseases responsive to therapy with interferon- beta (IFN-beata)
11/21/2002	US20020172654 Cosmetic or pharmaceutical compositions comprising homopolymers and salts thereof
11/21/2002	US20020172649 Pharmaceutical composition
11/21/2002	US20020172644 Nasal retention of medicaments in the nasal cavity for enhanced topical or systemic activity; therapy
11/21/2002	US20020170593 Non-stoichiometric non- equilibrium material, and the material is a nanostructured material.
11/21/2002	CA2778114A1 Abuse-resistant opioid dosage form
11/21/2002	CA2447494A1 Method for manufacture of fine particles
11/21/2002	CA2447444A1 Antisense permeation enhancers
11/21/2002	CA2447343A1 Method to induce neovascular formation and tissue regeneration

1 ... 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 ... 2991